Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Class:Id	LiteratureReference:9652226
_displayName	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
_timestamp	2019-06-28 18:10:51
author	[Person:9008919] Li, D [Person:9652238] Ambrogio, L [Person:9652235] Shimamura, T [Person:9652240] Kubo, S [Person:3301224] Takahashi, M [Person:9652233] Chirieac, L R [Person:9652222] Padera, R F [Person:9652288] Shapiro, G I [Person:9652221] Baum, A [Person:9652250] Himmelsbach, F [Person:9652286] Rettig, W J [Person:8941975] Meyerson, M [Person:9652276] Solca, F [Person:9652242] Greulich, H [Person:9652270] Wong, K-K
created	[InstanceEdit:9652267] Orlic-Milacic, Marija, 2019-06-28
journal	Oncogene
pages	4702-11
pubMedIdentifier	18408761
title	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
volume	27
year	2008
(literatureReference)	[Reaction:9652264] ERBB2 binds TKIs [Homo sapiens] [Pathway:9652282] Drug-mediated inhibition of ERBB2 signaling [Homo sapiens]
[Change default viewing format]

No pathways have been reviewed or authored by BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models (9652226)